7,710.30

-33.68

-0.43%

52,263.03

-212.07

-0.40%

26,175.18

-374.67

-1.41%

2,858.22

+27.71

+0.98%

4.9990

-0.0460

-0.91%

16.51

-0.40

-2.36%

4,033.40

-18.20

-0.45%

81,016.51

+268.48

+0.33%

Crude Oil Dec 26

101.42

-1.36

-1.32%

US Private Equity

10,940.50

+9.00

+0.08%

OTC Markets OTCPK - Delayed Quote USD

Daiichi Sankyo Company, Limited (DSKYF)

16.40 -0.20 (-1.20%)

As of October 28 at 4:00:00 PM EDT. Market Open.

Loading Chart for DSKYF

Chart Range Bar

Interval:

In partnership with ChartIQ

Anthropic IPO Filing, Steady Crude Prices Energize Asian Stock Markets

Anthropic IPO Filing, Steady Crude Prices Energize Asian Stock Markets

Enhertu® Approved in the EU as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer

Enhertu® Approved in the EU as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer

COLL vs. DSNKY: Which Stock Is the Better Value Option?

COLL vs. DSNKY: Which Stock Is the Better Value Option?

Daiichi Sankyo Co Ltd's Dividend Analysis

Daiichi Sankyo Co Ltd's Dividend Analysis

Daiichi Sankyo Highlights Ongoing Progress Across Industry-Leading ADC Portfolio with New Research Updates at ESMO

Daiichi Sankyo Highlights Ongoing Progress Across Industry-Leading ADC Portfolio with New Research Updates at ESMO

SMMT Inks Deal With AZN-Daiichi to Study Ivonescimab + Datroway Combos

SMMT Inks Deal With AZN-Daiichi to Study Ivonescimab + Datroway Combos

Will there be more to Daiichi’s story than DXd ADCs?

Will there be more to Daiichi’s story than DXd ADCs?

Summit Therapeutics (SMMT) Is Up 7.3% After $2 Billion AstraZeneca Partnership and Trial Collaboration

Summit Therapeutics (SMMT) Is Up 7.3% After $2 Billion AstraZeneca Partnership and Trial Collaboration

Sector Update: Healthcare Stocks Steady Late Afternoon

Sector Update: Healthcare Stocks Steady Late Afternoon

AstraZeneca Stocks Moves Lower as Datroway Combination Enters Phase 3

AstraZeneca Stocks Moves Lower as Datroway Combination Enters Phase 3

AstraZeneca deepens Summit ties on ADC-bispecific cancer combo testing pact

AstraZeneca deepens Summit ties on ADC-bispecific cancer combo testing pact

Mobilize your Website

View Site in Mobile | Classic

Share by: